In 2004, Woll and co-authors showed that the frequency of CD8+ T cells specific for the HER2/neu E75 epitope was about 0.2–0.3% of bulk peripheral blood lymphocytes in patients with HER2-positive breast cancer (31). Here, ERBB2 is linked to breast cancer.